10x Genomics Inc Class A (TXG)

Over the past six months, 10x Genomics' stock experienced several notable events. As of April 8, 2026, the share price was $23.04, a 165.74% increase from April 9, 2025. The Q3 2025 earnings release beat revenue expectations, leading to a 13.1% stock jump. The Q4 2025 earnings also exceeded market expectations. In March 2026, William Blair upgraded 10x Genomics to Outperform, and ARK Investment bought 92K shares. Management credited consumables growth and adoption of new products as key drivers, along with disciplined cost control.

While specific seasonality is not explicitly detailed, demand fluctuations are influenced by broader factors. Instrument sales have been impacted by customer capital expenditure constraints, while consumables show double-digit growth, suggesting a more consistent revenue stream. The company anticipates continued expansion in AI-driven biological research and growth in translational and clinical applications to drive future demand.

10x Genomics, Inc. is a US-based life science technology company that develops and sells instruments, consumables, and software for biological systems analysis, operating in the Healthcare sector. Its integrated solutions are designed to interrogate, understand, and master biology at a resolution and scale that matches the complexity of biological systems. Key product platforms include the Chromium platform for single-cell analysis, the Visium platform for spatial analysis, the Xenium platform for in situ analysis, and software products like Cell Ranger, Loupe Browser, and Xenium Explorer. 10x Genomics serves a diverse customer base, including academic, government, biopharmaceutical, biotechnology, and other institutions.

10x Genomics has a global presence, selling its products in the United States, the rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company maintains specific office locations in Jui Bei City, Taiwan; Shanghai, China; Singapore; and Tokyo, Japan.

In the past year, 10x Genomics has maintained a strong reputation for its innovative contributions to single-cell and spatial biology and is seen as a key player in AI-driven biological data. Partnerships reinforce its position in advancing research. Despite a challenging macroeconomic environment, the company's high-margin consumables continue to grow, signaling strengthening underlying demand. 10x Genomics holds a dominant market share in single-cell biology and is projected to expand this share further. Operational efficiency initiatives have also contributed positively to its market perception.

Ownership of 10x Genomics stock is predominantly held by institutional investors, estimated between 84.68% to 98.77%. Major institutional owners include Vanguard Group Inc, ARK Investment Management LLC, and BlackRock, Inc. Individual investors hold a smaller percentage, around 9.71% to 12.85%. Company insiders own about 2.52% to 9.39% of the company's shares. Paladin Capital Management LLC is a significant individual shareholder.